OxThera
Develops products for the treatment of metabolic disorders resulting from excess levels of oxalate.
Launch date
Market cap
-
Enterprise valuation
AUD218—326m (Dealroom.co estimates Nov 2016.)
Stockholms kommun Stockholm County (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.1m | 3.4m | - | 2.0m | 1.9m | <1m | - |
| % growth | 72 % | 65 % | - | - | (5 %) | (50 %) | - |
| EBITDA | (<1m) | (<1m) | (5.6m) | (4.1m) | (3.1m) | <1m | - |
| % EBITDA margin | (13 %) | (23 %) | - | (208 %) | (165 %) | 76 % | - |
| Profit | (2.0m) | (12.5m) | (8.1m) | (17.8m) | (18.8m) | (8.0m) | (<1m) |
| % profit margin | (99 %) | (366 %) | - | (903 %) | (1009 %) | (845 %) | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Corporate spinout | ||
€18.2m | Early VC | ||
€16.5m | Early VC | ||
€7.7m | Early VC | ||
* | €32.0m | Late VC | |
| Total Funding | AUD126m | ||
Related Content
Recent News about OxThera
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.